ID: MRFR/Pharma/2913-HCR | 206 Pages | Author: Rahul Gotadki | March 2024
Brief TOC
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3 Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
4 Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
5.1 Porters five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain
5.3 Investment Feasibility Analysis
5.4 Price Factor Analysis
6 Global Antihistamine drugs Market, by Type
6.1 Introduction
6.2 Sedating Antihistamine Drugs
6.2.1 Brompheniramine
6.2.2 Chlorpheniramine
6.2.3 Diphenhydramine
6.2.4 Doxylamine
6.2.5 Carbinoxamine
6.2.6 Others
6.3 Non-Sedating Antihistamine Drugs
6.3.1 Fexofenadine
6.3.2 Loratadine
6.3.3 Loratadine ODT
6.3.4 Others
7 Global Antihistamine Drugs Market, By Route of Administration
7.1 Introduction
7.2 Oral Route
7.3 Parenteral Route
7.3.1 Intramuscular
7.3.2 Subcutaneous
7.3.3 Intravenous Route
7.4 Rectal Route
8 Global Antihistamine Drugs Market, by Indication
8.1 Introduction
8.2 Allergy
8.3 Urticaria
8.4 Dermatitis
8.5 Others
9 Global Antihistamine Drugs Market by End User
9.1 Introduction
9.2 Hospitals
9.3 Clinics
9.4 Pharmaceutical Companies
9.5 Others
10 Global Antihistamine Drugs Market by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.2 Canada
10.2.2 Latin America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 UK
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Republic of Korea
10.4.5 Australia
10.4.6 Rest of Asia Pacific
10.5 Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of Middle East & Africa
11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments
12 Company Profiles
12.1 Johnson & Johnson Consumer Inc.
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 Sanofi
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Bayer AG
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Pfizer
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Merck Sharp & Dohme Corp.
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial Overview
12.5.4 Key Developments
12.6 Prestige Brands Holdings, Inc.
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 CVS Pharmacy
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Pharmaceutical Industry
14 Appendix
Market Segmentation
Antihistamine Drugs Type Outlook (USD Billion, 2018-2032)
Sedating
Non-Sedating
Antihistamine Drugs Route of Administration Outlook (USD Billion, 2018-2032)
Oral Route
Parenteral Route
Rectal Route
Antihistamine Drugs Indication Outlook (USD Billion, 2018-2032)
Allergy
Urticaria
Dermatitis
Antihistamine Drugs End User Outlook (USD Billion, 2018-2032)
Hospitals
Clinics
Pharmaceutical Companies
Antihistamine Drugs Regional Outlook (USD Billion, 2018-2032)
North America Outlook (USD Billion, 2018-2032)
North America Antihistamine Drugs by Type
Sedating
Non-Sedating
North America Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
North America Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
North America Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies
US Outlook (USD Billion, 2018-2032)
US Antihistamine Drugs by Type
Sedating
Non-Sedating
US Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
US Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
US Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies
Canada Outlook (USD Billion, 2018-2032)
Canada Antihistamine Drugs by Type
Sedating
Non-Sedating
Canada Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
Canada Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
Canada Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies
Europe Outlook (USD Billion, 2018-2032)
Europe Antihistamine Drugs by Type
Sedating
Non-Sedating
Europe Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
Europe Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
Europe Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies
Germany Outlook (USD Billion, 2018-2032)
Germany Antihistamine Drugs by Type
Sedating
Non-Sedating
Germany Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
Germany Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
Germany Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies
France Outlook (USD Billion, 2018-2032)
France Antihistamine Drugs by Type
Sedating
Non-Sedating
France Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
France Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
France Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies
UK Outlook (USD Billion, 2018-2032)
UK Antihistamine Drugs by Type
Sedating
Non-Sedating
UK Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
UK Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
UK Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies
Italy Outlook (USD Billion, 2018-2032)
Italy Antihistamine Drugs by Type
Sedating
Non-Sedating
Italy Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
Italy Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
Italy Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies
Spain Outlook (USD Billion, 2018-2032)
Spain Antihistamine Drugs by Type
Sedating
Non-Sedating
Spain Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
Spain Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
Spain Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies
Rest Of Europe Outlook (USD Billion, 2018-2032)
Rest Of Europe Antihistamine Drugs by Type
Sedating
Non-Sedating
Rest Of Europe Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
Rest Of Europe Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
Rest Of Europe Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies
Asia-Pacific Outlook (USD Billion, 2018-2032)
Asia-Pacific Antihistamine Drugs by Type
Sedating
Non-Sedating
Asia-Pacific Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
Asia-Pacific Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
Asia-Pacific Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies
China Outlook (USD Billion, 2018-2032)
China Antihistamine Drugs by Type
Sedating
Non-Sedating
China Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
China Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
China Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies
Japan Outlook (USD Billion, 2018-2032)
Japan Antihistamine Drugs by Type
Sedating
Non-Sedating
Japan Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
Japan Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
Japan Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies
India Outlook (USD Billion, 2018-2032)
India Antihistamine Drugs by Type
Sedating
Non-Sedating
India Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
India Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
India Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies
Australia Outlook (USD Billion, 2018-2032)
Australia Antihistamine Drugs by Type
Sedating
Non-Sedating
Australia Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
Australia Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
Australia Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies
Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)
Rest of Asia-Pacific Antihistamine Drugs by Type
Sedating
Non-Sedating
Rest of Asia-Pacific Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
Rest of Asia-Pacific Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
Rest of Asia-Pacific Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies
Rest of the World Outlook (USD Billion, 2018-2032)
Rest of the World Antihistamine Drugs by Type
Sedating
Non-Sedating
Rest of the World Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
Rest of the World Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
Rest of the World Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies
Middle East Outlook (USD Billion, 2018-2032)
Middle East Antihistamine Drugs by Type
Sedating
Non-Sedating
Middle East Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
Middle East Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
Middle East Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies
Africa Outlook (USD Billion, 2018-2032)
Africa Antihistamine Drugs by Type
Sedating
Non-Sedating
Africa Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
Africa Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
Africa Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies
Latin America Outlook (USD Billion, 2018-2032)
Latin America Antihistamine Drugs by Type
Sedating
Non-Sedating
Latin America Antihistamine Drugs by Route of Administration
Oral Route
Parenteral Route
Rectal Route
Latin America Antihistamine Drugs by Indication
Allergy
Urticaria
Dermatitis
Latin America Antihistamine Drugs by End User
Hospitals
Clinics
Pharmaceutical Companies